Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Hot Products

QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer

En-CPhI.CNDecember 03, 2019

Tag: QBiotics , head and neck cancer , tigilanol tiglate , HNSCC

PharmaSources Customer Service